Full text is available at the source.
Abstract
More than 236 million people globally are affected by peripheral artery disease (PAD), particularly those with type 2 diabetes.
- GLP-1 receptor agonists may provide cardiovascular and kidney benefits.
- The effects of GLP-1 receptor agonists on specific outcomes related to PAD are not well understood.
- This study aims to evaluate the long-term effects of GLP-1 receptor agonists on adverse outcomes in individuals with PAD.
Simplified